Genetically Engineered Mouse Models (GEMM) are transgenic animals in which gene knock-out and knock-in technologies have made it possible for us to more faithfully mimic the genetic and biological evolution of human cancers. GEMM studies by nature take longer to fill cohorts due to genetic mutations required for experimental animals due to more breeding required. The MP1U has 4 actively breeding models, 2 melanoma and 2 breast, available:
Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model.
Yoshidome K, Shibata M, Maroulakou I, Liu M, Jorcyk C, Gold L, Welch V and Green J: . Int J Oncol 12: 449-502, 1998; PMID: 9458374
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
Guy CT; Cardiff RD; Muller WJ: Mol Cell Biol 12(3):954-61 MGI: J:46460 PMID: 1312220
Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer.
Alwarawrah Y, Hughes P, Loiselle D, Carlson DA, Darr DB, Jordan JL, Xiong J, Hunter LM, Dubois LG, Thompson JW, Kulkarni MM, Ratcliff AN, Kwiek JJ, Haystead TA.
Cell Chem Biol. 2016 Jun 23;23(6):678-88. doi: 10.1016/j.chembiol.2016.04.011. Epub 2016 Jun 2. PMID: 27265747
- Braf v600E; Pten; Tyr-Cre
Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.
Usary J, Darr DB, Pfefferle AD, Perou CM.
Curr Protoc Pharmacol. 2016 Mar 18;72:14.38.1-11. doi: 10.1002/0471141755.ph1438s72. Review.
While GEMMS off whole animal microenvironment for tumor studies, the MP1U has the capability to ramp up project speeds by using syngeneic tumor grafts or cell line implants. Large cohorts of animals can be studied simultaneously to meet the requirements of the project. The current models we have readily available are:
- T11 (Breast)
- Braf PTEN Tyr-Cre (Melanoma)
- K14pBRCA1_B (Breast)
- BBN (Bladder)
- UPPL (Bladder)
- TRIA (Melanoma)
Differential response to exercise in claudin-low breast cancer.
Glass OK, Bowie M, Fuller J, Darr D, Usary J, Boss K, Choudhury KR, Liu X, Zhang Z, Locasale JW, Williams C, Dewhirst MW, Jones LW, Seewaldt V.
Oncotarget. 2017 Sep 19;8(60):100989-101004. doi: 10.18632/oncotarget.21054. eCollection 2017 Nov 24. PMID: 29254140